FIGURE 1.
FIGURE 2.
FIGURE 3.
Treatment characteristics (n = 228)
| Characteristic | ||
|---|---|---|
| Number of fractions | Number of tumors | % |
| 1 | 1 | 0.4 |
| 2 | 2 | 0.9 |
| 3 | 32 | 14.1 |
| 4 | 3 | 1.3 |
| 5 | 174 | 76.3 |
| 8 | 16 | 7.0 |
| Treatment characteristics | Median | Mean (range) |
| PTV volume (cc) | 22.4 | 30.6 (5.9–160.4) |
| PTV max dose % | 137.5 | 135.5 (104.7–151.4) |
| ITV coverage % | 100 | 99.7 (66.5–100) |
| PTV coverage (V95) % | 95 | 90.4 (32–100) |
| PTV coverage (V99) % | 99.8 | 99 (88.8–100) |
| BED | 115.5 | 112.3 (59.5–151.2) |
| Technique | Number of patents | % |
| 3D | 62 | 27.2 |
| ARC | 34 | 14.9 |
| VMAT | 132 | 57.9 |
Patient characteristics (n = 206)
| Characteristic | Number | % |
|---|---|---|
| Age mean in years (range) | 71.2 (53–89) | |
| Gender | ||
| Male | 113 | 54.9 |
| Female | 93 | 45.1 |
| Other malignancies* | ||
| yes | 96 | 46.6 |
| no | 110 | 53.4 |
| Number of comorbidities | ||
| 0–3 | 125 | 60.7 |
| > 3 | 81 | 39.3 |
| Lung function (%) | mean (range) | |
| FVC (data available for 153 pts) | 87.7 (24–152) | |
| FEV1 (data available for 164 pts) | 61.4 (17–144) | |
| DLCO (data available for 140 pts) | 55.6 (15–120) | |
| ECOG Performance status before radiotherapy | ||
| 0 | 17 | 8.3 |
| 1 | 78 | 37.9 |
| 2 | 81 | 39.2 |
| 3 | 30 | 14.6 |
| The reason for non-surgery | ||
| Impaired lung function | 92 | 44.7 |
| Comorbidity | 85 | 41.3 |
| Patient refused | 5 | 2.4 |
| Old age | 4 | 1.9 |
| Combined reasons | 20 | 9.7 |
Tumor characteristics (n = 228)
| Characteristic | Number | % |
|---|---|---|
| Histology | ||
| Adenocarcinoma | 84 | 36.8 |
| Squamous cell carcinoma | 38 | 16.7 |
| Small cell lung cancer | 4 | 1.8 |
| NSCLC unspecified | 19 | 8.3 |
| No tissue diagnosis | 82 | 36.0 |
| Carcinoid | 1 | 0.4 |
| Location | ||
| Left upper lobe | 78 | 34.2 |
| Left lower lobe | 31 | 13.6 |
| Right upper lobe | 73 | 32.0 |
| Right middle lobe | 11 | 4.8 |
| Right lower lobe | 35 | 15.4 |
| T stage | ||
| 1 | 194 | 85.1 |
| 2 | 27 | 11.8 |
| 3 | 7 | 3.1 |